Why Is ANAPTYSBIO INC (ANAB) Stock Moving Today?

Why ANAB stock is down today

AnaptysBio Inc (ANAB) fell 6.12% to $51.56 on Friday, marking a sharp reversal from its morning high. The stock opened with a 2.0% gap up but quickly reversed course as traders reacted to mixed signals from the company’s recent earnings report and broader market sentiment.

What Happened

AnaptysBio reported Q2 GAAP earnings of $5.11 per share, a significant improvement from a loss of $1.30 per share in the same period last year. The company also generated $27.5 million in revenue, up 23.5% year-over-year and $7.38 million above expectations. However, despite these positive figures, the stock declined sharply during the session. The company filed a Form 8-K with the SEC on September 21, 2026, disclosing its financial results and related documents. The filing included details of the company’s cash, cash equivalents, and investments, but did not include new product or partnership announcements that might have driven sustained optimism.

Retail traders and analysts have been divided in recent days. TD Cowen and HC Wainwright & Co. both maintain Buy ratings on ANAB, with price targets of $70 and $95, respectively. However, the stock’s performance on Friday suggests that investors are reassessing the valuation amid a broader market pullback and a lack of new catalysts.

What The Data Shows

The stock opened at $56.02, a 2.0% gap up from the prior close, but fell to a session low of $50.61 by midday. Volume was 0.2 million shares, or 0.4 times the 3-month daily average, indicating moderate participation. ANAB has a market cap of $1.6 billion and a beta of 0.41, suggesting it is less volatile than the broader market. The stock has traded between $20.49 and $73.30 over the past 52 weeks and is currently down 30.6% from its 52-week high. The company remains unprofitable with a trailing twelve-month net margin of -11.5% and an EPS of -0.95.

What To Watch

The stock is scheduled to report no upcoming earnings. Investors should monitor coverage breadth and analyst commentary for any shifts in sentiment ahead of the next earnings cycle.